Pharmacokinetic Allometric Scaling of Oligonucleotides

被引：10

作者：

Mahmood, Iftekhar ^{[1
]}

机构：

[1] US FDA, Off Blood Review & Res OBRR, Ctr Biol Evaluat & Res, Rockville, MD USA

来源：

NUCLEIC ACID THERAPEUTICS | 2011年 / 21卷 / 05期

关键词：

HUMAN DRUG CLEARANCE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE GEM-91; MODIFIED ANTISENSE OLIGONUCLEOTIDE; NECROSIS-FACTOR-ALPHA; PHASE-I TRIAL; INTRAVENOUS-INFUSION; PREDICTION; HUMANS; BCL-2; METABOLISM;

D O I：

10.1089/nat.2011.0299

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The objective of this study was to evaluate the predictive performance of interspecies scaling of oligonucleotides to predict clearance and volume of distribution at steady state in humans from animal data. The human pharmacokinetic parameters were predicted using 1, 2, or at least 3 animal species. The results of the study indicated that the pharmacokinetic parameters of oligonucleotides can be predicted with reasonable accuracy in humans when at least 3 animal species are employed. On the other hand, allometric scaling based on 1 or 2 species or fixed coefficient or fixed exponent can be erratic and unreliable. Further work should be conducted in this direction.

引用

页码：315 / 321

页数：7

共 50 条

[11] Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients
Malik, Paul R., V
Edginton, Andrea N.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (11): : 835 - 844
[12] Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
Johnson, Trevor N.
Ke, Alice B.
JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 : S83 - S93
[13] Allometric scaling of estuarine ecosystem metabolism
Nidzieko, Nicholas J.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (26) : 6733 - 6738
[14] Application of Allometric Scaling to Nanochelator Pharmacokinetics
Jones, Gregory
Zeng, Lingxue
Kim, Jonghan
ACS OMEGA, 2023, 8 (30): : 27256 - 27263
[15] Allometric prediction of the human pharmacokinetic parameters for naveglitazar
Ahlawat, Preeti
Srinivas, Nuggehally R.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2008, 33 (03) : 187 - 190
[16] Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling
Choi, Go-Wun
Lee, Yong-Bok
Cho, Hea-Young
PHARMACEUTICS, 2019, 11 (04):
[17] Allometric prediction of the human pharmacokinetic parameters for naveglitazar
Ahlawat P.
Srinivas N.R.
European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33 (3) : 187 - 190
[18] The ontogeny of the chin: an analysis of allometric and biomechanical scaling
Holton, N. E.
Bonner, L. L.
Scott, J. E.
Marshall, S. D.
Franciscus, R. G.
Southard, T. E.
JOURNAL OF ANATOMY, 2015, 226 (06) : 549 - 559
[19] The Authors' Reply: Obesity and Allometric Scaling of Pharmacokinetics
Diepstraten, Jeroen
Knibbe, Catherijne A. J.
CLINICAL PHARMACOKINETICS, 2011, 50 (11) : 755 - 756
[20] Prediction of Clearance and Dose ofMidazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling
Mansoor, Najia
Ahmad, Tasneem
Khan, Rafeeq Alam
Sharib, Syed Mohammad
Mahmood, Iftekhar
AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (01) : E32 - E37

← 1 2 3 4 5 →